お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
964953

フィブリノゲン濃縮製剤の世界市場:成長、動向、予測(2020年~2025年)

Fibrinogen Concentrate Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 117 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
フィブリノゲン濃縮製剤の世界市場:成長、動向、予測(2020年~2025年)
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 117 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

フィブリノゲン濃縮製剤の市場規模は、予測期間中に健全なCAGRで成長すると予測されています。市場成長の主な要因は、出血性疾患の有病率の増加と、フィブリノゲン濃縮製剤に関連する承認の数の増加です。英国医師血友病協会(United Kingdom Doctor's Hemophilia Association)の調査によると、2018年、凝固障害のある人は英国で約1万1,089人でした。さらに、2016年に、LFBは製品FibClotを販売するために、欧州で規制当局の承認を受けました。したがって、これらの要因は、フィブリノゲン濃縮製剤の需要を刺激すると予想されます。

当レポートではフィブリノゲン濃縮製剤の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、適応症別・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • 血液障害の負担の増加
    • 製品承認の増加
  • 市場の抑制要因
    • 厳格な規制の枠組み
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 適応症別
    • 先天性フィブリノーゲン欠乏症
    • 外科的処置
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東とアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • CSL Behring
    • Hualan Biological Engineering Inc.
    • LFB
    • Molecular Innovations Inc.
    • Octapharma AG
    • Shanghai RAAS

第7章 市場機会と動向

目次
Product Code: 68566

The fibrinogen concentrate market is expected to register a healthy CAGR during the forecast period. The major contributing factor for the growth of this market is the increasing prevalence of bleeding disorders and an increase in the number of approvals related to fibrinogen concentrate. According to the study of United Kingdom Doctor's Hemophilia Association, in 2018, people with coagulation defects were around 11,089 in the United Kingdom. Furthermore, in 2016, LFB received its regulatory approval in Europe to market the product, FibClot. Hence, these factors are expected to fuel the demand for fibrinogen concentrate.

Key Market Trends

Congenital Fibrinogen Deficiency Segment is Expected to Register Significant Growth in the Fibrinogen Concentrate Market

  • Congenital Fibrinogen Deficiency is expected to register a higher growth in the fibrinogen concentrate market owing to the higher prevalence of hemophilia and development in products related to fibrinogen. According to the National Hemophilia Foundation, currently, worldwide the prevalence of hemophilia is more than 400,000. Furthermore, approximately 75% of the affected population still do not receive proper treatment.
  • According to the study published in the year 2019 by the Journal of Thrombosis and Haemostasis, Fibclot and Clottafact, a human fibrinogen concentrate was found to provide effective therapy for the patients with fibrinogen deficiency. Hence, the rising prevalence of bleeding disorders and the safety and efficacy of human fibrinogen concentrate is expected to propel the fibrinogen concentrate market growth in this segment.

North America is Expected to Hold a Significant Share in the Market and this is Expected Remain the Same in the Forecast Period

North America expected to hold a major market share in the global fibrinogen concentrate market due to the increasing burden of bleeding disorders and rising geriatric population. According to the U.S. Census Bureau, in 2018, people aged 65 and above were accounted to be approximately 52 million. Acquired hemophilia, a rare autoimmune disorder, is quite predominant in the geriatric population. According to the National Organization of Rare Disorders, at least 1-2 people per 1,000,000 are affected by the acquired hemophilia in the United States. Around 50% of the affected population the underlying disorders are difficult to identify. Also, according to the National Hemophilia Foundation, Von Willebrand Disease is one of the common bleeding disorders that affects around 1% of the population every year in the United States. Hence, such factors are affected to drive market growth in the North America region.

Competitive Landscape

Various companies are taking initiatives to improve their presence in the market. In 2019, Octapharma AG received approval for Fibryga, a fibrinogen concentrate, to be marketed in 15 European countries. Few of the companies that are currently dominating the market are LFB, Molecular Innovations Inc., Octapharma AG, CSL Behring, Shanghai RAAS, and Hualan Biological Engineering Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Blood Disorders
    • 4.2.2 Increasing Product Approvals
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Indication
    • 5.1.1 Congenital Fibrinogen Deficiency
    • 5.1.2 Surgical Procedure
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 CSL Behring
    • 6.1.2 Hualan Biological Engineering Inc.
    • 6.1.3 LFB
    • 6.1.4 Molecular Innovations Inc.
    • 6.1.5 Octapharma AG
    • 6.1.6 Shanghai RAAS

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.